AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide
Androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells
(CTCs) was demonstrated to predict poor treatment response in metastatic castrationresistant
prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide.
To develop a practical and robust liquid profiling approach for direct quantification of
AR-V7 in peripheral whole blood without the need of CTC capturing and to determine
its potential to predict treatment response in mCRPC patients.